Dupixent® (dupilumab) is now approved in India for the treatment of adults with moderate-to-severe atopic dermatitis
Sanofi Healthcare India Pvt. Ltd. today announced that it has received marketing authorisation for Dupixent® (dupilumab), the first biologic medicine […]
